SCHEMBL4915093

SCHEMBL4915093

Cc1cccc(O)c1NC(=O)Nc1cc(C(N)=O)ccc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 3/20 0.48
DRD2 P14416 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2B P41595 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
PKM P14618 1/20 0.42
PARP1 P09874 2/20 0.41
DDX3X O00571 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27701184 0.82 HDAC1 (0.42) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4923902 0.82 RAB9A (0.51) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4924988 0.80 CA12 (0.57) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4929091 0.79 LYN (0.43) DRD2HTR2AHTR2BSMN1; SMN2ALDH1A1
SCHEMBL27681865 0.77 CXCR2 (0.57) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4921362 0.76 MEN1 (0.58) CA12CA1CA2CA9POLB
SCHEMBL4915647 0.75 LCK (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4359936 0.75 KCNMA1 (0.62) CA12CA1CA2CA9POLB
SCHEMBL4925227 0.75 RAB9A (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4920330 0.74 MDM4 (0.46) CA12CA1CA2CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
EP-1796681-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF Genmedica Therapeutics SL (ES) 2007-06-20 EP disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
WO-2006013209-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF GENMEDICA THERAPEUTICS SL (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3438/4885CA1 2819/4885CA2 3279/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3541/4885CA1 3000/4885CA2 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.